TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06377072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
Study: NCT05749848
Drug: [¹⁴C]-LY3372689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06139536
Drug: BAT4706 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Study: NCT06139536
Drug: BAT1308 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Study: NCT02911961
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
Study: NCT05181852
Drug: IP2015, dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT05181852
Drug: IP2015, dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT05181852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05966246
Drug: Arm I : Experimental (Prucalopride succinate group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
Study: NCT05966246
Drug: Arm II : Control (Mosapride citrate group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control gourp taking mosapride citrate from day 1 day 5 after surgery
Study: NCT04572867
Drug: IV Diuretics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
Study: NCT05564442
Drug: 20% benzocaine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study: NCT05118334
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study: NCT06218199
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT03244072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracameral injection
Study: NCT05270460
Drug: PCS12852
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCS12852 oral tablet administered once daily
Study: NCT05270460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator oral tablet administered once daily
Study: NCT05849779
Drug: Intravenous sedation (current practice)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP).
Study: NCT06384248
Drug: LTC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Study: NCT06313801
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
Study: NCT05972044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken once daily
Study: NCT06134830
Drug: RAI
Normalized name: PRAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive iodine
Study: NCT04326478
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
Study: NCT05918107
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06131580
Drug: Intervention/Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: osilodrostat~- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Study: NCT05576480
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply every 3 weeks from week 3 for 4 cycles
Study: NCT05629468
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antibiotic
Study: NCT04847375
Drug: exogenous surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized Surfactant would be administered by face mask which has a nebulizer
Study: NCT04603508
Drug: BERLIM 25/10 association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berlim 25/10 association coated tablet.
Study: NCT04603508
Drug: ROSUVASTATIN CALCIUM
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 mg coated tablet.
Study: NCT05629468
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotics
Study: NCT06422429
Drug: Traditional deep-fried Youtiao
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45g 4 times a week for 4 months
Study: NCT05320380
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT05320380
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05320380
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT05816070
Drug: IVIEW-1201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times per day for day 1-2 and three times per day for day 3-7
Study: NCT06576271
Drug: GSK4527363
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4527363 will be administered to participants.
Study: NCT06576271
Drug: Placebo matching GSK4527363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK4527363 will be administered to participants.
Study: NCT05382182
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
Study: NCT04645823
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate 20 µg in 2 ml of saline injected into csf
Study: NCT05756972
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05756972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04645823
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
Study: NCT05690698
Drug: Quatiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic
Study: NCT05438251
Drug: Fespixon Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks
Study: NCT04965870
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
Study: NCT06213610
Drug: Prestarium® A tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
Study: NCT05948774
Drug: MT200605 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Study: NCT05948774
Drug: MT200605 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Study: NCT05608070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion at the rate of 83.3 ml/h.
Study: NCT06495931
Drug: HR20033 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR20033 tablets, nine times
Study: NCT06402968
Drug: Alternate IV Antihypertensive Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Study: NCT05838209
Drug: test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone oil used as an adjunctive of scaling and root planing and control,
Study: NCT05823870
Drug: DW6014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast
Study: NCT05491447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment
Study: NCT05178693
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cedazuridine 100mg + 35mg decitabine
Study: NCT06113848
Drug: Intra-Arterial TNK and Albumin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
Study: NCT06113848
Drug: Intra-Arterial TNK
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study population was divided into four groups, one of which had intra-arterial TNK .
Study: NCT06113848
Drug: Intra-Arterial Albumin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study population was divided into four groups, one of which had intra-arterial albumin.
Study: NCT05023278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo filled pill daily for 7 consecutive days.
Study: NCT00000937
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05226897
Drug: YYC405-T placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Study: NCT04886518
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study: NCT05049343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution.
Study: NCT05200728
Drug: SIM1910-09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Study: NCT05200728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Study: NCT05576584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
Study: NCT04806633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this arm will receive placebo.
Study: NCT05098418
Drug: Poison
Normalized name: Plant poison
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
Study: NCT04787211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given by intravenous administration
Study: NCT05923892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
Study: NCT04992546
Drug: PRN473 (SAR444727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white gel suspension
Study: NCT04992546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white gel suspension
Study: NCT06342648
Drug: Diclofenac Sodium injection
Normalized name: diclofenac sodium Injection
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of intramuscular diclofenac sodium
Study: NCT06366334
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT02533219
Drug: 18 F-DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
Study: NCT06196918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
Study: NCT02436044
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
Study: NCT02436044
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
Study: NCT05493540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen
Study: NCT05291572
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: brain stimulant
Study: NCT05264558
Drug: Epclusa 400Mg-100Mg Tablet
Normalized name: Epclusa 400mg-100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same day HCV test and treatment
Study: NCT05651516
Drug: 18F-PI-2620 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
Study: NCT04639843
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
Study: NCT06332040
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
Study: NCT05121831
Drug: DGX-001Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 of DGX-001
Study: NCT05121831
Drug: DGX-001 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2 of DGX-001
Study: NCT05121831
Drug: DGX-001 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3 of DGX-001
Study: NCT05121831
Drug: DGX-001 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4 of DGX-001
Study: NCT05307341
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
Study: NCT05592041
Drug: Banaba Leaf Extract
Normalized name: banaba leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: a herbal extract in the form of Bigel
Study: NCT01600001
Drug: KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01600001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05552807
Drug: SCT200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04824222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
Study: NCT04824222
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard COVID 19 pharmacological treatment
Study: NCT06093945
Drug: SHR2554 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 350mg taken on Day 1 and Day 10
Study: NCT06236230
Drug: levodopa/carbidopa/entacapone
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study.
Study: NCT04939779
Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration